Biotech Values

[ghmm]

NKTR:

I listened to the R&D Day (5 hours!) and will probably go over it a couple more times. As far as their known programs not a whole lot of new information was revealed.

The program is basically three parts
-Pain
-Oncology
-Preclinical programs (this had a lot of info not talked about before).

I had added to my underwater position a few dollars again and in hindsight should have added more. My concern then was the financing overhang which HR partial addressed. IF they didn't have the 102 spend they could actually be in pretty good financial position going forward. If 118 makes it to filing and approval NKTR has quite significant milestone payments.

They didn't give the full 102 Ovarian data yet but did mention about once have it talking with the FDA about an accelerated filing still though it seems really remote at this stage.